Key Takeaway: Vor Bio, a clinical-stage biotechnology company, has announced its participation in two upcoming investor conferences. The events include a fireside chat at the TD Cowen Virtual Immunology & Inflammation Summit on November 12, 2025, and another at the 8th Annual Evercore Healthcare Conference on December 2, 2025, in Miami, FL. The company is focused on advancing its treatment for autoimmune diseases through its lead candidate, telitacicept.
Price reaction · baseline $18.97 (2025-11-06 close) · hit pre-market · 3 other VOR headline(s) in the window, move may be shared
day 0 close · peak
-1.4%
Market Sentiment Analysis
POSITIVE FACTORS
Vor Bio is actively participating in investor conferences.
The company is advancing its treatment for autoimmune diseases.
Telitacicept is in Phase 3 clinical development.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+442%
120-day peak, hindsight
Typical move
18.8%
average across 6 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
Telitacicept
Phase 3 · Primary Sjogren's Disease
Full Press Release Details
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences:
TD Cowen VirtualImmunology & Inflammation SummitFireside Chat: Wednesday, November 12, 2025, at 2:30pm ET
A live webcast and archived replay of the fireside chats will be available on the investors section ofwww.vorbio.com.
About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visitwww.vorbio.com.